Cytokine Profiles as Potential Prognostic and Therapeutic Markers in SARS-CoV-2-Induced ARDS
Francesco Salton,Paola Confalonieri,Giuseppina Campisciano,Rossella Cifaldi,Clara Rizzardi,Daniele Generali,R. Pozzan,S. Tavano,C. Bozzi,Giulia Lapadula,Gianfranco Umberto Meduri,Marco Confalonieri,Manola Comar,Selene Lerda,Barbara Ruaro +14 more
Reads0
Chats0
TLDR
Patients in the IMV group had higher inflammation levels at intubation than the NIV group, which may indicate a higher resistance to glucocorticoids, which could indicate a better control of inflammation and a better outcome.Abstract:
Background. Glucocorticoids (GCs) have been shown to reduce mortality and the need for invasive mechanical ventilation (IMV) in SARS-CoV-2-induced acute respiratory distress syndrome (ARDS). It has been suggested that serum cytokines levels are markers of disease severity in ARDS, although there is only limited evidence of a relationship between the longitudinal cytokine profile and clinical outcomes in patients with SARS-CoV-2-induced ARDS treated with GC. Methods. We conducted a single-center observational study to investigate serial plasma cytokine levels in 17 patients supported with non-invasive ventilation (NIV) in order to compare the response in five patients who progressed to IMV versus 12 patients who continued with NIV alone. All patients received methylprednisolone 80 mg/day continuous infusion until clinical improvement. Results. The study groups were comparable at baseline. All patients survived. Although IL-6 was higher in the NIV group at baseline, several cytokines were significantly higher in the IMV group on day 7 (IL-6, IL-8, IL-9, G-CSF, IP-10, MCP-1, MIP-1α) and 14 (IL-6, IL-8, IL-17, G-CSF, MIP-1α, RANTES). No significant differences were observed between groups on day 28. Conclusions. Patients in the IMV group had higher inflammation levels at intubation than the NIV group, which may indicate a higher resistance to glucocorticoids. Higher GC doses or a longer treatment duration in these patients might have allowed for a better control of inflammation and a better outcome. Further studies are required to define the prognostic value of cytokine patterns, in terms of both GC treatment tailoring and timely initiation of IMV.read more
Citations
More filters
Journal ArticleDOI
Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: A prospective cohort study
Mattia Bellan,Daria Apostolo,Alice Albè,Martina Crevola,N Errica,G. Ratano,Stelvio Tonello,Rosalba Minisini,Davide D'Onghia,Alessio Baricich,Filippo Patrucco,Patrizia Zeppegno,Carla Gramaglia,Piero Emilio Balbo,Giuseppe Cappellano,Sara Casella,Annalisa Chiocchetti,Elisa Clivati,Mara Giordano,M. J. Manfredi,Giuseppe Patti,David J. Pinato,Chiara Puricelli,Davide Raineri,Roberta Rolla,Pier Paolo Sainaghi,Mario Pirisi +26 more
TL;DR: In this paper , the authors identify risk factors for the development of COVID-19 sequelae in a prospective cohort of subjects hospitalized for SARS-CoV-2 infection and followed up one year after discharge.
Journal ArticleDOI
Severe COVID-19 ARDS Treated by Bronchoalveolar Lavage with Diluted Exogenous Pulmonary Surfactant as Salvage Therapy: In Pursuit of the Holy Grail?
Barbara Ruaro,Paola Confalonieri,R. Pozzan,S. Tavano,L. Mondini,Elisa Baratella,Alessandra Pagnin,Selene Lerda,Pietro Geri,Marco Biolo,Marco Confalonieri,Francesco Salton +11 more
TL;DR: Combining the administration of diluted, exogenous pulmonary surfactant via bronchoalveolar lavage along with the standard therapy for SARS-CoV-2-induced ARDS may be a promising way of improving the management of ARDS.
Journal ArticleDOI
Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)
Francesco Salton,Paola Confalonieri,Stefano Centanni,Michele Mondoni,Nicola Petrosillo,Paolo Bonfanti,Giuseppe Lapadula,Donato Lacedonia,Antonio Voza,Nicoletta Carpenè,Marcella Montico,Nicolò Reccardini,Gianfranco Umberto Meduri,Barbara Ruaro,Marco Confalonieri +14 more
TL;DR: In this article , a multicentre, open-label RCT was conducted to investigate methylprednisolone 80 mg as a continuous daily infusion for 8 days followed by slow tapering versus dexamethasone 6 mg once daily for up to 10 days in adult patients with COVID-19 pneumonia requiring oxygen or noninvasive respiratory support.
Journal ArticleDOI
Thromboembolic Disease and Cardiac Thrombotic Complication in COVID-19: A Systematic Review
TL;DR: Despite moving into the endemic phase of the disease in most countries, thromboembolic complications in COVID-19 remain an entity that substantially impacts the health care system, with long-term effects that remain uncertain.
Journal ArticleDOI
Lung fibrosis: Post-COVID-19 complications and evidences
TL;DR: In this paper , the authors discussed several important pathways which are involved in post-COVID PF and highlighted the rationale for the use of antifibrotic agents to decrease the burden and improve pulmonary functions in COVID-19 patients.
References
More filters
Journal ArticleDOI
Acute respiratory distress syndrome: the Berlin Definition.
Ards Definition Task Force,V. Marco Ranieri,Gordon D. Rubenfeld,B. Taylor Thompson,Niall D. Ferguson,Ellen Caldwell,Eddy Fan,Luigi Camporota,Luigi Camporota,Arthur S. Slutsky +9 more
TL;DR: The updated and revised Berlin Definition for ARDS addresses a number of the limitations of the AECC definition and may serve as a model to create more accurate, evidence-based, critical illness syndrome definitions and to better inform clinical care, research, and health services planning.
Journal ArticleDOI
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Turk Rhen,John A. Cidlowski +1 more
TL;DR: This review summarizes the understanding of how glucocorticoids inhibit inflammation and give rise to side effects.
Journal ArticleDOI
Heat Shock Protein A12B Protects Vascular Endothelial Cells Against Sepsis-Induced Acute Lung Injury in Mice
TL;DR: The administration of HSPA12B siRNA aggravated lung pathological injury, upregulated pro-inflammatory cytokine expression, and increased myeloperoxidase activity, neutrophil infiltration, pulmonary edema, and pulmonary endothelial cell apoptosis protected against sepsis-induced ALI.
Journal ArticleDOI
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.
Sterne Jac.,Srinivas Murthy,Janet V. Diaz,Arthur S. Slutsky,Judit Villar,Derek C. Angus,Djillali Annane,Azevedo Lcp.,Otavio Berwanger,Alexandre Biasi Cavalcanti,Dequin P-F.,Dequin P-F.,Bin Du,Jonathan Emberson,David Fisher,Bruno Giraudeau,Anthony C. Gordon,Anders Granholm,Cameron Green,Richard Haynes,N Heming,Higgins Jpt.,Higgins Jpt.,Peter Horby,Peter Jüni,Martin J Landray,A. Le Gouge,Marie Leclerc,Wei Shen Lim,Flávia Ribeiro Machado,Colin McArthur,Colin McArthur,Ferhat Meziani,Morten Hylander Møller,Anders Perner,M W Petersen,Jelena Savović,Jelena Savović,Bruno Martins Tomazini,Viviane C Veiga,Steven A R Webb,John C. Marshall +41 more
TL;DR: A prospective meta-analysis that pooled data from 7 randomized clinical trials that evaluated the efficacy of corticosteroids in 1703 critically ill patients with COVID-19 found that low-dose dexamethasone reduced mortality in hospitalized patients with Cohen's disease who required respiratory support.
Journal ArticleDOI
Glucocorticoid resistance in inflammatory diseases
Peter J. Barnes,Ian M. Adcock +1 more
TL;DR: Several molecular mechanisms of glucocorticoid resistance have now been identified, including activation of mitogen-activated protein (MAP) kinase pathways by certain cytokines, excessive activation of the transcription factor activator protein 1, reduced histone deacetylase-2 (HDAC2) expression, and increased P-glycoprotein-mediated drug efflux.